Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03193593 · ClinicalTrials.gov registry record · Phase 2
Study to Evaluate EB-001 in Reducing Musculoskeletal Pain
A Phase 2 study, sponsored by Bonti.
- Completed
- Registry status
- Phase 2
- Development phase
- 66
- Enrollment target
NCT03193593 is a Phase 2 study that has completed, run by Bonti. The registered enrollment target is 66 participants.
The verdict
NCT03193593, a Phase 2 study, has completed, sponsored by Bonti.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 66 participants
- Enrollment target
Study Summary
To determine the safety and efficacy of single intra-operative treatment of EB-001 IM injections into the Pectoralis Major (PM) in subjects undergoing breast augmentation with subpectoral implants
Interventions
- DRUG Placebo
- DRUG EB-001
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 66 participants |
| Start Date | 2017-08-29 |
| Est. Completion | 2018-08-07 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03193593
The ClinicalTrials.gov registry entry for NCT03193593 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 66 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Bonti, which has 3 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT03193593 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03193593 about?
NCT03193593 is a clinical study titled "Study to Evaluate EB-001 in Reducing Musculoskeletal Pain". To determine the safety and efficacy of single intra-operative treatment of EB-001 IM injections into the Pectoralis Major (PM) in subjects undergoing breast augmentation with subpectoral implants
What is the current status of trial NCT03193593?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 66 participants. The study started on 2017-08-29. Estimated completion is 2018-08-07.
What interventions are being tested in trial NCT03193593?
The interventions under investigation include: Placebo (DRUG), EB-001 (DRUG).
Who is sponsoring clinical trial NCT03193593?
This trial is sponsored by Bonti, which has 3 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.